Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Impact of prior therapies on efficacy of belantamab mafodotin in R/R myeloma

Sagar Lonial • 19 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin
DREAMM-2

Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, discusses how the number of prior therapies affects the efficacy of single-agent belantamab mafodotin, an anti-BCMA immunoconjugate, in relapsed or refractory (R/R) multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals